Abstract
While the main function of the skin is to protect an organism against dehydration and external stress, it is more or less permeable to some chemical substances and may allow the permeation of certain drugs for therapeutic purposes. The observation of professional intoxications challenged by this permeability has triggered research in this field. Depending on the type and level of therapeutic activity sought in the drug and excipients used in the formulation, one finds it possible to class the different dermatological preparations into three groups:
-
1
Epidermal preparations: drugs are used to treat the epidermis, and only a superficial penetration limited to the epidermis is designed in order to achieve a local action. This type of application is used, for instance, in cosmetology (e.g., sunscreen preparations) and in therapy in the case of antifungal powders
-
2
Endodermal preparations: penetration of drugs must be deeper and pass through the stratum corneum and attain the dermis without reaching the general circulation, which, e.g., is the case with anti-inflammatory preparations containing corticoids
-
3
Transdermal preparations: in this case, the skin is used as a route of administration for drugs. A local action on the muscle underlying the skin may be achieved. However, as a general rule, a systemic action is achieved after the permeation of drugs in the general circulation: transdermal systems currently represent the most characteristic example. For this case, we will only discuss general bioavailability with respect to the other formulations for which it will only be question of topical availability
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ademola, J., and Meibach, H., 1995, Cutaneous metabolism and penetration of methoxypsoralen,betamethasone, retinoic acid, nitroglycerin and theophyllin, Current Prob. Dermatol 22:201-213
Aiache, J.-M., Cardot, J.-M., and Aiache, S., 1989, Comparative study of release kinetics of trinitrine from TTS, Int. J. Pharm. 55:147-155
Aiache, J.-M., Beyssac, E., and Cardot, J.-M., 1997, Les corrélations in vitro/in vivo, in: Traité de biopharmacie et de pharmacocinétique, PUM and Lavoisier, Montreal and Paris
Baker, H., 1979, The skin as a barrier, in: Textbook of Dermatology (A. Rook, D. S. Wilkinson, and F. S. G. Eblin), Blackwell, Oxford
Banerjee, P., and Robinson, J., 1991, Novel drug delivery systems, Clin. Pharmacokinet. 20:1-14
Behl, C., Kumar, S., Malick, A. W., Patel, S. B., Char, H., and Piemontese, D., 1990, Choice of membranes for in vitro skin uptake studies and general experimental techniques, in: Methods for Skin Absorption. (B. W. Kemppainen, and W. G. Reifenraft, eds.), CRC Press, Boca Raton
Bonina, F. P., and Montenegro, L. 1992, Penetration enhancer effects on in vitro percutaneous absorption of heparin sodium salt, Int. J. Pharm. 82:171-177
Boyd, R., Yang, B., Abel, R., Eldon, M., Sedman, A.,and Forgues, S., 1996, Pharmacokinetics of a 7 day l7β estradiol transdermal delivery system: Effect of application site and repeated applications on serum concentrations of oestradiol and estrone, J. Clin. Pharmacol. 36:998-1005
Bronaugh, R. L., and Stewart, R. F., 1986, Methods for in vitro percutaneous absorption studies: VI. Preparation of the barrier layer, J. Pharm. Sci. 75:487-491
Bronaugh, R. L., and Franz, T. J., 1986, Vehicle effects on percutaneous absorption: in vivo and in vitro comparisons with human skin, Br. J. Dermatol. 115:1-2
Cappel, M. J., and Kreuter, J., 1991, Effect of nonionic surfactants on transdermal drug delivery: II. Poloxamer and poloxamine surfactants, Int. J. Pharm. 69:155-167
Cardot, J. M., and Beyssac, E., 1993, In vitro/in vivo correlations: Scientific implications and standardisation, Eur. J. Drug Meth. Pharmacokinet. 18:113-120
Caterall, R. A., 1997, Problems of sweating and transdermal fentanyl, Palliative Med. 11:169-170
Dupuis, D., Rougier, A., Roguet, R., Lotte, C., and Kalopissis, G., 1984, In vivo relationship between horny layer reservoir effect and percutaneous absorption in human and rat, J. Invest. Dermatol 82:353-356
ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals), 1993, Percutaneous absorption, Monograph No. 20
EP: European Pharmacopoeia, 1997, Dissolution test for transdermal patches, 3rd Ed., Council of Europe, Strasbourg, pp. 131-133
FDA Guidance, 1995, Topical dermatologic corticosteroids: In vivo bioequivalence, Rockville, MD
Franz, T. J., 1975, In vitro vs. in vivo percutaneous absorption: The relevance of in vitro data, J. Invest. Dermatol. 64:190-195
Friend,D. R., 1992, In vitro skin permeation techniques, J. Control Rel. 18:235-248
Fujimara, A., Sasaki, M., Harada, K., Kamugai, Y., Ohashi, K., and Ebihara, A., 1996, Influence of bathing and hot weather on the pharmacokinetics of new transdermal clonidine, M-5041-T, J. Pharm. Clin. 36:892-896
Grissom, R. E., Brownie, C., and Guthrie, F. E., 1987, In vivo and in vitro dermal penetration of lipophilic and hydrophilic pesticides in mice, Bull. Environ. Contam. Toxicol. 38:917
Guy, R. H., 1996, Current status and future prospects of transdermal drug delivery, Pharm. Res. 13:1765-1769
Guy, R. R., Hadgraft, J., and Buck, D., 1987, Transdermal drug delivery and cutaneous metabolism, Xenobiotica 17:325-343
Hadgraft, J., Wolff, M, Bonn, R., and Cordes, G., 1990, Development of biphasic transdermal nitroglycerin delivery systems Int. J. Pharm. 64:187-194
Hadgraft, J., Beutner, D., and Wolff, H., 1993, In vivo-in vitro comparisons in the transdermal delivery of nitroglycerin, Int. J. Pharm. 89:Rl-R4
Haigh, J. M., and Kanfer, I., 1984, Assessment of topical corticosteroid preparations: The human skin blanching assay, Int. J. Pharm. 19:245-262
Itoh, T., Magavi, R., Casady, R. L., Nishihata, T., and Rytting, J. H., 1990, A method to predict the percutaneous permeability of various compounds: shed snake skin as a model membrane, Pharm. Res. 7(12):13O2-13O6
Keshary, P. R., and Chien, Y. W., 1984, Mechanisms of controlled nitroglycerin administration (I): Development of a finite-dosing skin permeation system and transport of model compound, Drug Dev. Ind. Pharm 10:883-913
Kligman, A. M., 1983, A biological brief on percutaneous absorption. Drug Dev. Ind. Pharm. 9:521
Nastruzzi, C., Esposito, E., Pastesini, C., Gambari, R., and Menegatti, E., 1993, Comparative study on the release kinetics of methylnicotinate from topic formulation. Int. J. Pharm. 90:43-50
Neurbert, R., Bendas, C., Wohlrab, W., Gienau, B., and Furst, W., 1991, A multilayer membrane system for modelling drug penetration into skin, Int. J. Pharm. 75:89-94
Paire, M., 1977, Contribution à 1’évaluation biopharmaceutique des préparations à usage dermatologique, thése de Doctorat en Pharmacie, Clermont-Ferrand, France
Poulsen, B. J., 1970, The use of models in estimating vehicle effects on the activity of topical corticosteroidformulations. Br. J. Dermatol 82 (Suppl. 6):49-52
Poulsen, B. J., Young, E., Coquilla, V., and Katz, M., 1986, Effect of topical vehicle composition on the in vitro release of fluocinolone acetonide and its acetate ester, J. Pharm. Sci. 57:928-933
Rosdy, M., Pisani, A., and Ortonne, J.-P., 1993, Production of basement membrane components by a reconstructed epidermis cultured in the absence of serum and dermal factors, Br. J. Dermatol. 129:227-234
Shah, V. P., Elkins, J., and Skelly, J. P., 1992, Relationship between in vivo skin blanching and in vitro release rate for betamethasone valerate creams, J. Pharm. Sci 81(1): 104-106
Skelly, J. P., Shah, V. P., Maibach, H. I., Guy, R. H., Wester, R. C, Flynn, G., and Yacobi, A., 1987, FDA and AAPS report of the workshop on principles and practises of in vitro percutaneous penetration studies: Relevance to bioavailability and bioequivalence, Pharm. Res. 4(3):265-267
Slivka, S. R., Landeen, L. K., Zeigler, F., Zimber, M., and Bartel, R. L., 1993, Characterisation, barrier function, and drug metabolism of an in vitro model, J. Invest. Dermatol 100:40-46
Tojo, K., and Lee, A. C, 1989, A method for predicting steady-state rate of skin penetration in vivo; J. Invest. Dermatol. 92:105
Treffel, P., and Gabard, B., 1996, Skin penetration and sun protection factor of ultra violet filters from two vehicles, Pharm. Res. 13:770-774
USP: United States Pharmacopia, 1995, USP 23, 1995, Drug release <724>, 1796-1799
Van Buskirk, G. A., Gonzales, M. A., Sha, V., Barnhardt, S., Barrett, C., Berge, S., Cleary, G., Chan, K., Flynn, G., Foster, T., Gale, R., Garrison, R., Gochnour, S., Gotto, A., Govil, S., Gray, V. A., Hammar, J., Harder, S., Hoiberg, C., Hussain, A., Karp, C., Llanos, H., Mantelle, J., Noonan, P., Swanson, D., and Zerbe, H., 1997, Scale-up of adhesive transdermal drug delivery systems, Pharm. Res l4(7):848- 852
Zatz, J. L., 1983, Factors in percutaneous absorption, in: Pharmacokinetics and Topically Applied Cosmetics (J. McNemey and A. Curry, eds.), CFTA Scientific Monograph Series No. 2, Cosmetic, Toiletry and Fragance Association, Inc., Washington DC
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Beyssac, E., Cardot, J.M., Bonnabry, C. (2000). In Vitro/In Vivo Correlations. In: Schwindt, D.A., Maibach, H.I. (eds) Cutaneous Biometrics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1199-1_27
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1199-1_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5437-6
Online ISBN: 978-1-4615-1199-1
eBook Packages: Springer Book Archive